Dyne Therapeutics reported net income of -$178.77M for the quarter ended Jun 2026. This income statement covers 28 quarters of results from Sep 2019 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Income Statement | Sep2019 | Dec2019 | Mar2020 | Jun2020 | Sep2020 | Dec2020 | Mar2021 | Jun2021 | Sep2021 | Dec2021 | Mar2022 | Jun2022 | Sep2022 | Dec2022 | Mar2023 | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Outstanding (Entity)Shares Outstanding (Entity.) | 51.48M | 51.57M | 51.65M | 51.73M | 51.91M | 55.64M | 58.31M | 61.01M | 61.32M | 61.47M | 87.09M | 100.12M | 101.75M | 102.32M | 113.63M | 114.34M | 142.61M | 128.44M | 165.20M | 165.67M | ||||||||
| Operating items | ||||||||||||||||||||||||||||
| Research & DevelopmentR&D | 36.51M | 42.30M | 28.24M | 46.66M | 34.67M | 33.19M | 37.54M | 59.13M | 55.25M | 58.84M | 44.54M | 62.26M | 92.80M | 81.81M | 106.45M | 99.24M | 97.22M | 95.43M | 100.89M | 152.17M | ||||||||
| Selling, General & AdministrativeSG&A | 6.26M | 9.66M | 7.55M | 6.09M | 7.61M | 6.96M | 7.93M | 7.61M | 7.02M | 8.84M | 24.62M | 9.70M | 12.86M | 15.30M | 15.93M | 16.55M | 16.67M | 20.70M | 24.39M | 29.49M | ||||||||
| Other Operating ExpensesOther Opex | -0.01M | -0.03M | 0.01M | -0.01M | -0.02M | -0.22M | -0.37M | -0.13M | -0.70M | 0.51M | -0.19M | -0.74M | -0.03M | -0.09M | -1.60M | 0.28M | -0.29M | -0.13M | -0.09M | |||||||||
| Operating ExpensesOpex | 42.77M | 51.96M | 35.78M | 52.76M | 42.28M | 40.15M | 45.46M | 66.74M | 62.27M | 67.69M | 69.16M | 71.96M | 105.66M | 97.11M | 122.37M | 115.79M | 113.89M | 116.13M | 125.28M | 181.66M | ||||||||
| Operating IncomeOp. Inc | -42.77M | -51.96M | -35.78M | -52.76M | -42.28M | -40.15M | -45.46M | -66.74M | -62.27M | -67.69M | -69.16M | -71.96M | -105.57M | -97.11M | -122.37M | -115.79M | -113.89M | -116.13M | -125.28M | -181.66M | ||||||||
| EBIT | -42.77M | -51.96M | -35.78M | -52.76M | -42.28M | -40.15M | -45.46M | -66.74M | -62.27M | -67.69M | -69.16M | -71.96M | -105.57M | -97.11M | -122.37M | -115.79M | -113.89M | -116.13M | -125.28M | -181.66M | ||||||||
| Non-operating items | ||||||||||||||||||||||||||||
| Non Operating Interest Expenses | 0.09M | 2.90M | ||||||||||||||||||||||||||
| Interest & Investment IncomeInt & Inv Inc | 0.18M | 0.18M | -0.66M | -0.23M | 0.90M | 1.34M | 0.37M | 0.15M | 2.19M | 1.75M | -0.13M | -0.11M | 9.28M | 7.59M | 0.23M | 6.62M | 8.48M | 7.66M | -0.61M | 7.79M | ||||||||
| Other Non Operating IncomeOther Non Op Inc. | 0.18M | 0.17M | 0.20M | 0.45M | 0.89M | 1.32M | 1.28M | 1.83M | 2.06M | 1.05M | 3.51M | 6.86M | 8.53M | 7.57M | 7.01M | 4.93M | 5.85M | 4.17M | 4.42M | 3.10M | ||||||||
| Net income details | ||||||||||||||||||||||||||||
| EBT | -42.58M | -51.78M | -36.44M | -52.98M | -41.38M | -38.80M | -45.10M | -66.59M | -60.08M | -65.94M | -69.29M | -72.07M | -96.29M | -89.52M | -122.14M | -109.26M | -108.32M | -108.47M | -125.89M | -173.87M | ||||||||
| Profit After TaxPAT | -42.58M | -52.02M | -35.58M | -52.30M | -41.38M | -38.41M | -44.19M | -64.90M | -60.21M | -66.64M | -65.65M | -65.10M | -97.12M | -89.54M | -115.36M | -110.86M | -108.04M | -111.95M | -120.85M | -178.77M | ||||||||
| Income from Continuing OperationsIncome (Continuing) | -42.58M | -51.78M | -36.44M | -52.98M | -41.38M | -38.80M | -45.10M | -66.59M | -60.08M | -65.94M | -69.29M | -72.07M | -96.29M | -89.52M | -122.14M | -109.26M | -108.32M | -108.47M | -125.89M | -173.87M | ||||||||
| Consolidated Net IncomeConsol Net Inc. | -42.58M | -51.78M | -36.44M | -52.98M | -41.38M | -38.80M | -45.10M | -66.59M | -60.08M | -65.94M | -69.29M | -72.07M | -96.29M | -89.52M | -122.14M | -109.26M | -108.32M | -108.47M | -125.89M | -173.87M | ||||||||
| Income towards Parent CompanyParent Net Inc | -42.58M | -51.78M | -36.44M | -52.98M | -41.38M | -38.80M | -45.10M | -66.59M | -60.08M | -65.94M | -69.29M | -72.07M | -96.29M | -89.52M | -122.14M | -109.26M | -108.32M | -108.47M | -125.89M | -173.87M | ||||||||
| Net Income towards Common StockholdersNet Income | -42.58M | -51.78M | -36.44M | -52.98M | -41.38M | -38.80M | -45.10M | -66.59M | -60.08M | -65.94M | -69.29M | -72.07M | -96.29M | -89.52M | -122.14M | -109.26M | -108.32M | -108.47M | -125.89M | -173.87M | ||||||||
| Additional items | ||||||||||||||||||||||||||||
| EPS (Basic) | -0.83 | -1.02 | -0.71 | -1.03 | -0.80 | -0.75 | -0.80 | -1.11 | -0.98 | -1.10 | -0.85 | -0.78 | -0.95 | -0.95 | -1.11 | -0.96 | -0.76 | -0.84 | -0.76 | -1.05 | ||||||||
| EPS (Diluted) | -0.83 | -1.02 | -0.71 | -1.03 | -0.80 | -0.75 | -0.80 | -1.11 | -0.98 | -1.10 | -0.85 | -0.78 | -0.95 | -0.95 | -1.11 | -0.96 | -0.76 | -0.84 | -0.76 | -1.05 | ||||||||
| Shares Outstanding | 51.32M | 50.90M | 51.60M | 51.68M | 51.80M | 51.98M | 56.33M | 59.84M | 61.11M | 59.68M | 81.04M | 92.51M | 100.88M | 94.14M | 109.91M | 113.87M | 141.81M | 128.44M | 165.04M | 165.45M | ||||||||
| Shares Outstanding (Diluted)Shares Outstanding (Dil.) | 51.32M | 50.90M | 51.60M | 51.68M | 51.80M | 51.98M | 56.33M | 59.84M | 61.11M | 59.68M | 81.04M | 92.51M | 100.88M | 94.14M | 109.91M | 113.87M | 141.81M | 128.44M | 165.04M | 165.45M | ||||||||
| EBITDA | -42.77M | -51.96M | -35.78M | -52.76M | -42.28M | -40.15M | -45.46M | -66.74M | -62.27M | -67.69M | -69.16M | -71.96M | -105.57M | -97.11M | -122.37M | -115.79M | -113.89M | -116.13M | -125.28M | -181.66M | ||||||||
| Interest ExpensesInt Expense | 0.09M | 2.90M |